We are live on ! Find out more
STRO icon

Sutro Biopharma

43 hedge funds and large institutions have $97.3M invested in Sutro Biopharma in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

34% more funds holding

Funds holding: 3243 (+11)

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

0.5% less ownership

Funds ownership: 5.24%4.75% (-0.5%)

29% less capital invested

Capital invested by funds: $137M → $97.3M (-$40.2M)

Holders
43
Holders Change
+11
Holders Change %
+34.38%
% of All Funds
0.96%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
22
Increased
8
Reduced
7
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AGM
51
Alpine Global Management
New York
-$375K -2,500 Closed
Walleye Trading
52
Walleye Trading
New York
-$319K -2,126 Closed
BCM
53
BlueCrest Capital Management
Jersey
-$165K -1,100 Closed

STRO Hedge Fund Activity: Q4 2018 in Review

43 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2018, worth a combined $97.3M — down 29% from $137M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new STRO positions and 10 closed out — a net gain of 12 holders — while 8 added to existing stakes and 7 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $1.6M. The largest seller was Cowen Inc, exiting entirely with an estimated $6.26M sold.

  • 43 institutional investors held Sutro Biopharma (STRO) as of Q4 2018, up from 32 in Q3 2018.
  • Funds reported $97.3M of Sutro Biopharma stock for Q4 2018, down 29% quarter-over-quarter.
  • 22 funds opened new Sutro Biopharma positions in Q4 2018 and 10 closed out, a net change of +12 holders.
  • The largest Sutro Biopharma buyer in Q4 2018 was Sphera Funds Management, an estimated $1.6M added.
  • The largest Sutro Biopharma seller in Q4 2018 was Cowen Inc, an estimated $6.26M sold.

Based on aggregated 13F filings for Q4 2018.